AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16214626 — intervention group
Group type: COMPARATOR
Intervention: Orthodontists and laypeople
Number of subjects: 40
Study 14720054 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 0
Study 14720054 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 10204976 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient cardiac counseling and rehabilitation
Number of subjects: 100
Study 10204976 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended cardiac counseling and rehabilitation
Number of subjects: 100
Study 10204976 — intervention group
Group type: COMPARATOR
Intervention: Normal care (Control group)
Number of subjects: 100
Study 7772354 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl patch (75 micrograms/hr) for 72 hours
Number of subjects: 40
Study 7772354 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 40
Study 2306747 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 21
Study 2306747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 6771814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxazolam as a tranquilizer
Number of subjects: 0
Study 6771814 — intervention group
Group type: COMPARATOR
Intervention: Control (no tranquilizer)
Number of subjects: 0
Study 31876397 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Individual and Family Cognitive Behavioural Therapy (IFCBT)
Number of subjects: 70
Study 31876397 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 70
Study 31422012 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffolds (BVS)
Number of subjects: 0
Study 31422012 — intervention group
Group type: COMPARATOR
Intervention: Contemporary drug-eluting stents (DES)
Number of subjects: 0
Study 30502442 — intervention group
Group type: EXPERIMENTAL
Intervention: LS + MLS swaps (similar alternatives with 5-20% less salt and alternatives with >20% less salt)
Number of subjects: 947
Study 30502442 — intervention group
Group type: COMPARATOR
Intervention: LS swaps (similar alternatives with 5-20% less salt)
Number of subjects: 947
Study 28425735 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-led Body Project
Number of subjects: 680
Study 28425735 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led Body Project
Number of subjects: 680
Study 28425735 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based eBody Project
Number of subjects: 680
Study 28425735 — intervention group
Group type: COMPARATOR
Intervention: eBody Project
Number of subjects: 680
Study 26457334 — intervention group
Group type: EXPERIMENTAL
Intervention: High readiness to change with poorer health perceptions
Number of subjects: 495
Study 26457334 — intervention group
Group type: EXPERIMENTAL
Intervention: High readiness to change with comparable or better health perceptions
Number of subjects: 495
Study 22878432 — intervention group
Group type: EXPERIMENTAL
Intervention: Sativex (oromucosal), self-titrated to symptom relief or maximum tolerated dose (maximum of 130 mg THC and 120 mg CBD daily)
Number of subjects: 146
Study 20634174 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate 500 mcg daily
Number of subjects: 59
Study 20634174 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate 1000 mcg daily
Number of subjects: 59
Study 20634174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 19850374 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory scheduled handwashing (IS)
Number of subjects: 652
Study 19850374 — intervention group
Group type: COMPARATOR
Intervention: Usual handwashing practices (CS)
Number of subjects: 652
Study 17854241 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium augmentation
Number of subjects: 29
Study 17854241 — intervention group
Group type: COMPARATOR
Intervention: Phenelzine
Number of subjects: 29
Study 15100590 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 201
Study 15100590 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg
Number of subjects: 201
Study 15100590 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen/codeine 600/60 mg
Number of subjects: 201
Study 15100590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 11706665 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. artesunate
Number of subjects: 69
Study 11706665 — intervention group
Group type: COMPARATOR
Intervention: i.v. artesunate plus i.v. quinine
Number of subjects: 69
Study 11706665 — intervention group
Group type: COMPARATOR
Intervention: i.v. quinine
Number of subjects: 69
Study 9292761 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet (170 mmol Na/d)
Number of subjects: 14
Study 9292761 — intervention group
Group type: COMPARATOR
Intervention: Low sodium diet (60 mmol Na/d)
Number of subjects: 14
Study 8424304 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoesophageal echocardiography (TEE)
Number of subjects: 30
Study 8424304 — intervention group
Group type: COMPARATOR
Intervention: ECG
Number of subjects: 30
Study 8424304 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative myocardial infarction
Number of subjects: 30
Study 2955899 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline 250 mg BID for four months
Number of subjects: 40
Study 2955899 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin 250 mg BID for four months
Number of subjects: 40
Study 2955899 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 40
Study 2955899 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 40
Study 30779100 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral immunonutrition (EIN)
Number of subjects: 50
Study 30779100 — intervention group
Group type: COMPARATOR
Intervention: Oral diet (OD)
Number of subjects: 50
Study 28388232 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electric nerve stimulation (TENS) for 15 minutes around the patella.
Number of subjects: 17
Study 28388232 — intervention group
Group type: COMPARATOR
Intervention: Repeated single-legged squats (RSLS) until pain was within 1 cm of pain during an exhaustive run or 10 sets.
Number of subjects: 17
Study 26148595 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐1 combined with oxaliplatin
Number of subjects: 70
Study 26148595 — intervention group
Group type: COMPARATOR
Intervention: Xeloda combined with oxaliplatin
Number of subjects: 70
Study 24036849 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training on a cycle-ergometer or aquatic-bike, 30 min daily at 60% of VO2peak for 3 weeks
Number of subjects: 60
Study 21502634 — intervention group
Group type: EXPERIMENTAL
Intervention: Danoprevir monotherapy
Number of subjects: 0
Study 21502634 — intervention group
Group type: COMPARATOR
Intervention: Pegylated interferon and ribavirin treatment
Number of subjects: 0
Study 18032491 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8(+) T-cell peptide epitope vaccine
Number of subjects: 14
Study 18032491 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaccine
Number of subjects: 14
Study 16957147 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.5 mg/kg)
Number of subjects: 3528
Study 16957147 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.75 mg/kg)
Number of subjects: 3528
Study 16957147 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 3528
Study 15326399 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Practitioner
Number of subjects: 75
Study 15326399 — intervention group
Group type: COMPARATOR
Intervention: Physician
Number of subjects: 75
Study 10937002 — intervention group
Group type: EXPERIMENTAL
Intervention: Learn, Share & Live breast cancer education program
Number of subjects: 240
Study 9278196 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of felbamate (600 mg or 1200 mg)
Number of subjects: 35
Study 9278196 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of felbamate (600 mg or 1200 mg every 12 h)
Number of subjects: 35
Study 9278196 — intervention group
Group type: COMPARATOR
Intervention: Control group (young healthy volunteers)
Number of subjects: 35
Study 8350886 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (6 g daily for one year)
Number of subjects: 66
Study 3548601 — intervention group
Group type: EXPERIMENTAL
Intervention: Tartrazine
Number of subjects: 24
Study 3548601 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoic acid
Number of subjects: 24
Study 3548601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31648850 — intervention group
Group type: EXPERIMENTAL
Intervention: Health guidance with dietary instructions focusing on meal sequence (Group B)
Number of subjects: 42
Study 31648850 — intervention group
Group type: EXPERIMENTAL
Intervention: Health guidance with dietary instructions focusing on nutritional balance (Group C)
Number of subjects: 42
Study 31648850 — intervention group
Group type: COMPARATOR
Intervention: Conventional health guidance (Group A)
Number of subjects: 42
Study 28917361 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercises (20 minutes, including single leg stretch, pelvic press, swimming, kneeling opposite arm and leg reach)
Number of subjects: 46
Study 28917361 — intervention group
Group type: COMPARATOR
Intervention: Control group (rest period)
Number of subjects: 46
Study 25039961 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-mediated communication-focused treatment
Number of subjects: 0
Study 25039961 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent behaviour (mediator)
Number of subjects: 0
Study 25039961 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediation analysis
Number of subjects: 0
Study 23400425 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX group (group D, n = 30)
Number of subjects: 60
Study 23400425 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C, n = 30)
Number of subjects: 60
Study 21220402 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of cold tap water at home
Number of subjects: 961
Study 21220402 — intervention group
Group type: EXPERIMENTAL
Intervention: Total water consumption
Number of subjects: 961
Study 21220402 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottled water consumption
Number of subjects: 961
Study 21220402 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fluid consumption
Number of subjects: 961
Study 21220402 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of ≥ 6 μg/day of bromodichloromethane
Number of subjects: 961
Study 19066291 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise (approximately 80% VO(2max)) for 60 weeks, 5 sessions per week, 120 min each session.
Number of subjects: 286
Study 19066291 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity exercise (approximately 60% VO(2max)) for 60 weeks, 5 sessions per week, 120 min each session.
Number of subjects: 286
Study 19066291 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (moderate and high intensity)
Number of subjects: 286
Study 19066291 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (moderate and high intensity) during recovery period
Number of subjects: 286
Study 17693687 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive information about the ergogenic aid
Number of subjects: 42
Study 17693687 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative information about the ergogenic aid
Number of subjects: 42
Study 15198780 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterbirth
Number of subjects: 80
Study 15198780 — intervention group
Group type: COMPARATOR
Intervention: Land birth
Number of subjects: 80
Study 15198780 — intervention group
Group type: COMPARATOR
Intervention: Preference arm (non-randomised)
Number of subjects: 80
Study 11474387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg; 2 doses) with NAP
Number of subjects: 187
Study 11474387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg; 1 dose) with PEG-EL
Number of subjects: 187
Study 11474387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg)
Number of subjects: 187
Study 11474387 — intervention group
Group type: COMPARATOR
Intervention: NAP
Number of subjects: 187
Study 11474387 — intervention group
Group type: COMPARATOR
Intervention: PEG-EL
Number of subjects: 187
Study 9605803 — intervention group
Group type: EXPERIMENTAL
Intervention: Three full doses of PRP-T or PRP-CRM197
Number of subjects: 627
Study 9605803 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional-dose regimens (one half or one third of the full dose)
Number of subjects: 627
Study 9605803 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of PRP-T
Number of subjects: 627
Study 9605803 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of PRP-CRM197
Number of subjects: 627
Study 8581408 — intervention group
Group type: EXPERIMENTAL
Intervention: BT 563 (10 mg/day for 12 days)
Number of subjects: 38
Study 8581408 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin (CyA) and low dose steroids
Number of subjects: 38
Study 340129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular methotrexate (5 mg, two injections of 2.5 mg a week apart)
Number of subjects: 42
Study 340129 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular triamcinolone hexacetonide (20 mg, single injection)
Number of subjects: 42
Study 31350798 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical autologously sourced PRP added to a preservative cosmetic base applied twice daily for 8 weeks
Number of subjects: 20
Study 31350798 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control serum applied twice daily for 8 weeks
Number of subjects: 20
Study 27624149 — intervention group
Group type: EXPERIMENTAL
Intervention: D1 receptor antagonist fluphenazine (FLU; 3 mg)
Number of subjects: 30
Study 27624149 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 receptor antagonist haloperidol (HAL; 3 mg)
Number of subjects: 30
Study 27624149 — intervention group
Group type: COMPARATOR
Intervention: d-amphetamine (AMPH; 20 mg)
Number of subjects: 30
Study 26051201 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month adherence program and statin medication
Number of subjects: 7640
Study 26051201 — intervention group
Group type: COMPARATOR
Intervention: Statin medication only
Number of subjects: 7640
Study 23396354 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics
Number of subjects: 37
Study 21943331 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation (SG)
Number of subjects: 90
Study 21943331 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education (EG)
Number of subjects: 90
Study 21943331 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 90
Study 19136486 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine 5 mg b.i.d. for 2 months, increased to 7.5 mg b.i.d. for a further 2 months
Number of subjects: 889
Study 19136486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 889
Study 17359211 — intervention group
Group type: EXPERIMENTAL
Intervention: Air abrasion + acid etching
Number of subjects: 30
Study 17359211 — intervention group
Group type: COMPARATOR
Intervention: Air abrasion
Number of subjects: 30
Study 17359211 — intervention group
Group type: COMPARATOR
Intervention: Acid etching with 37% orthophosphoric acid
Number of subjects: 30
Study 15508522 — intervention group
Group type: EXPERIMENTAL
Intervention: Dummy dentition with simulated cavity preparation by 5 operators.
Number of subjects: 5
Study 11446892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg t.i.d. for 2 weeks
Number of subjects: 21
Study 11446892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 11446892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 21
Study 9560544 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp infiltration with 0.5% bupivacaine
Number of subjects: 13
Study 9560544 — intervention group
Group type: COMPARATOR
Intervention: Control group (no scalp infiltration)
Number of subjects: 13
Study 7935682 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation from HLA-identical siblings
Number of subjects: 255
Study 7935682 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 255
Study 3191940 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg at 6 p.m. (Fam 6)
Number of subjects: 9
Study 3191940 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg at 10 p.m. (Fam 10)
Number of subjects: 9
Study 3191940 — intervention group
Group type: COMPARATOR
Intervention: Placebo at 6 p.m. and 10 p.m.
Number of subjects: 9
Study 31507100 — intervention group
Group type: EXPERIMENTAL
Intervention: HALF-MIS (8 sessions over 3-4 weeks)
Number of subjects: 38
Study 31507100 — intervention group
Group type: COMPARATOR
Intervention: Control (treatment as usual)
Number of subjects: 38
Study 29734405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryolipolysis (temperature -7°C, suction power 30 kPa, application time 60 min)
Number of subjects: 15
Study 26602300 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant feeding and/or water, sanitation, and hygiene interventions
Number of subjects: 0
Study 26602300 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 23247974 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery with adjuvant therapy
Number of subjects: 40
Study 23247974 — intervention group
Group type: COMPARATOR
Intervention: Primary chemoradiotherapy
Number of subjects: 40
Study 21200077 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled loxapine (5 mg)
Number of subjects: 344
Study 21200077 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled loxapine (10 mg)
Number of subjects: 344
Study 21200077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 344
Study 21200077 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled loxapine
Number of subjects: 344
Study 20020380 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous fetoscopic endoluminal tracheal occlusion (FETO)
Number of subjects: 0
Study 20020380 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 0
Study 17635415 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrate (0.1 mmol kg(‐1) day‐1)
Number of subjects: 9
Study 17635415 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (placebo)
Number of subjects: 9
Study 15583115 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone (1 g/d)
Number of subjects: 63
Study 15583115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 11583752 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred self-management training and follow-up on request
Number of subjects: 203
Study 11583752 — intervention group
Group type: COMPARATOR
Intervention: Normal treatment and follow-up (control group)
Number of subjects: 203
Study 9621835 — intervention group
Group type: EXPERIMENTAL
Intervention: Attended words (read aloud)
Number of subjects: 0
Study 9621835 — intervention group
Group type: EXPERIMENTAL
Intervention: Ignored words (not read aloud)
Number of subjects: 0
Study 9621835 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous presentation of two words with attentional manipulation
Number of subjects: 0
Study 9621835 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct remembering
Number of subjects: 0
Study 9621835 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect remembering
Number of subjects: 0
Study 7870244 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscopic discectomy
Number of subjects: 80
Study 7870244 — intervention group
Group type: COMPARATOR
Intervention: Non-microscopic discectomy (interlaminar approach)
Number of subjects: 80
Study 2897197 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazifylline 5 mg
Number of subjects: 24
Study 2897197 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazifylline 10 mg
Number of subjects: 24
Study 2897197 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazifylline 15 mg
Number of subjects: 24
Study 31392822 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg dulaglutide
Number of subjects: 5770
Study 31392822 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg dulaglutide
Number of subjects: 5770
Study 31392822 — intervention group
Group type: COMPARATOR
Intervention: Active comparator or placebo
Number of subjects: 5770
Study 28872920 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone (60 mg intravenous)
Number of subjects: 123
Study 28872920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 25828541 — intervention group
Group type: EXPERIMENTAL
Intervention: Jefferson Scale of Empathy (JSE) during clinical training
Number of subjects: 4797
Study 25828541 — intervention group
Group type: EXPERIMENTAL
Intervention: Jefferson Scale of Empathy (JSE) during preclinical training
Number of subjects: 4797
Study 25828541 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive effort
Number of subjects: 4797
Study 25828541 — intervention group
Group type: COMPARATOR
Intervention: Confirmatory factor analysis models
Number of subjects: 4797
Study 25568568 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (2 µg/kg IV bolus) + Nitroglycerin (400 µg/spray, 2 puffs)
Number of subjects: 80
Study 25568568 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (2 µg/kg IV bolus)
Number of subjects: 80
Study 22334468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 0
Study 22334468 — intervention group
Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE) Group
Number of subjects: 0
Study 19875736 — intervention group
Group type: EXPERIMENTAL
Intervention: ancrod (0.167 IU/kg per hour)
Number of subjects: 500
Study 19875736 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 500
Study 19875736 — intervention group
Group type: EXPERIMENTAL
Intervention: ancrod
Number of subjects: 500
Study 17319860 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized weight loss approach
Number of subjects: 36
Study 15638092 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) DCR group
Number of subjects: 130